{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:59:18Z","timestamp":1790632758297,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T00:00:00Z","timestamp":1598745600000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-15-CE18-0032"],"award-info":[{"award-number":["ANR-15-CE18-0032"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.exer.2019.107754","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T12:23:51Z","timestamp":1565267031000},"page":"107754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence"],"prefix":"10.1016","volume":"187","author":[{"given":"Elodie","family":"Bousquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Daruich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2019.107754_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000489673","article-title":"Towards an optimized use of ocular corticosteroids: EURETINA award lecture 2017","volume":"240","author":"Behar-Cohen","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.exer.2019.107754_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000480652","article-title":"The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature","volume":"46","author":"Belden","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.exer.2019.107754_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamaophthalmol.2015.1320","article-title":"Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography","volume":"133","author":"Bonini Filho","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.exer.2019.107754_bib4","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib5","first-page":"2505","volume":"vol. 35","author":"Bousquet","year":"2015"},{"key":"10.1016\/j.exer.2019.107754_bib6","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study","volume":"33","author":"Bousquet","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2016.02.012","article-title":"Shift work: a risk factor for central serous chorioretinopathy","volume":"165","author":"Bousquet","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2018.09.034","article-title":"Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy","volume":"198","author":"Bousquet","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib9","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s00417-016-3373-3","article-title":"Clinical experience with eplerenone to treat chronic central serous chorioretinopathy","volume":"254","author":"Cakir","year":"2016","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib10","article-title":"New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure","author":"Capelli","year":"2019","journal-title":"J. Nephrol."},{"key":"10.1016\/j.exer.2019.107754_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00169099","article-title":"Long-term follow-up of central serous retinopathy in 150 patients","volume":"81","author":"Castro-Correia","year":"1992","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial","volume":"115","author":"Chan","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archopht.118.9.1211","article-title":"Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy","volume":"118","author":"Chappelow","year":"2000","journal-title":"Arch. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2019.107754_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"Cheung","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.exer.2019.107754_bib15","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/OPTH.S86778","article-title":"Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy","volume":"9","author":"Chin","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1573402113666170228151402","article-title":"Vascular consequences of aldosterone excess and mineralocorticoid receptor antagonism","volume":"13","author":"Chrissobolis","year":"2017","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1016\/j.exer.2019.107754_bib17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1097\/IAE.0000000000000998","article-title":"CHOROIDAL THICKNESS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY: assessment of haller and sattler layers","volume":"36","author":"Chung","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2019.107754_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2019.107754_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.5.2.2","article-title":"Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy","volume":"5","author":"Daruich","year":"2016","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"10.1016\/j.exer.2019.107754_bib21","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1097\/IAE.0000000000001443","article-title":"Acute central serous chorioretinopathy: factors influencing episode duration","volume":"37","author":"Daruich","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib22","first-page":"97","article-title":"The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease","volume":"26","author":"Davel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.exer.2019.107754_bib23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ophtha.2014.09.026","article-title":"Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration","volume":"122","author":"de Jong","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib24","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"30 Years of the Mineralocorticoid Receptor: the role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib25","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1097\/IAE.0000000000001773","article-title":"Indocyanine green angiography of pachychoroid pigment epitheliopathy","volume":"38","author":"Ersoz","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib26","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2019.107754_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/jovr.jovr_139_16","article-title":"Visual and anatomical outcomes of spironolactone therapy in patients with chronic central serous chorioretinopathy","volume":"12","author":"Falavarjani","year":"2017","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.exer.2019.107754_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bjo.72.11.829","article-title":"Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy","volume":"72","author":"Ficker","year":"1988","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ophtha.2014.09.034","article-title":"One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy","volume":"122","author":"Fujita","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib30","doi-asserted-by":"crossref","first-page":"T17","DOI":"10.1530\/JOE-17-0119","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor activation and specificity-conferring mechanisms: a brief history","volume":"234","author":"Funder","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib31","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.12688\/f1000research.11887.1","article-title":"Spironolactone in cardiovascular disease: an expanding universe?","volume":"6","author":"Funder","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.exer.2019.107754_bib32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","article-title":"Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes","volume":"37","author":"Gergely","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study","volume":"36","author":"Ghadiali","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib34","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/jpet.106.105668","article-title":"Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin","volume":"318","author":"Ghanem","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.exer.2019.107754_bib35","first-page":"221","article-title":"The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity","volume":"8","author":"Golestaneh","year":"2002","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2019.107754_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10633-014-9475-5","article-title":"Pattern ERG in central serous retinopathy","volume":"130","author":"Goyal","year":"2015","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archopht.1994.01090200063023","article-title":"Digital indocyanine green videoangiography of central serous chorioretinopathy","volume":"112","author":"Guyer","year":"1994","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ophtha.2003.09.024","article-title":"Risk factors for central serous chorioretinopathy: a case-control study","volume":"111","author":"Haimovici","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib39","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1210\/mend.14.8.0502","article-title":"Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor","volume":"14","author":"Hellal-Levy","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib40","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00417-014-2780-6","article-title":"Spironolactone in the treatment of central serous chorioretinopathy - a case series","volume":"252","author":"Herold","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib41","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1073\/pnas.1802212115","article-title":"CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy","volume":"115","author":"Hosoda","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.exer.2019.107754_bib42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","article-title":"Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy","volume":"29","author":"Imamura","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ophtha.2010.08.017","article-title":"Fundus autofluorescence and visual acuity in central serous chorioretinopathy","volume":"118","author":"Imamura","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib44","first-page":"9450297","article-title":"Poor sleep quality is the risk factor for central serous chorioretinopathy","author":"Ji","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.exer.2019.107754_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000444058","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis","volume":"56","author":"Kapoor","year":"2016","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2019.107754_bib46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.exer.2019.107754_bib47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/HYPERTENSIONAHA.117.10437","article-title":"Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging","volume":"71","author":"Kim","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.107754_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib49","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00195356","article-title":"Contrast sensitivity after resolution of central serous retinopathy","volume":"232","author":"Koskela","year":"1994","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","article-title":"A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"170","author":"Lai","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/IAE.0000000000001913","article-title":"Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy","volume":"39","author":"Lee","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/IAE.0000000000000287","article-title":"PACHYCHOROID: an inherited condition?","volume":"35","author":"Lehmann","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5301\/ejo.5000727","article-title":"Eplerenone in patients with chronic recurring central serous chorioretinopathy","volume":"26","author":"Leisser","year":"2016","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy","volume":"22","author":"Loo","year":"2002","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib57","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/13816810.2018.1536219","article-title":"Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G\/5G gene polymorphisms in central serous chorioretinopathy","volume":"39","author":"Malle","year":"2018","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.exer.2019.107754_bib58","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.ophtha.2010.01.023","article-title":"Subfoveal choroidal thickness after treatment of central serous chorioretinopathy","volume":"117","author":"Maruko","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib59","series-title":"Risk Factors for Recurrences of Central Serous Chorioretinopathy","author":"Matet","year":"2017"},{"key":"10.1016\/j.exer.2019.107754_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"M\u00e9nard","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0002-9394(03)00076-X","article-title":"Central serous chorioretinopathy associated with administration of sympathomimetic agents","volume":"136","author":"Michael","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib62","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ophtha.2013.11.020","article-title":"Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy","volume":"121","author":"Miki","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib63","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1167\/iovs.18-25497","article-title":"Genome-wide association study to identify a new susceptibility locus for central serous chorioretinopathy in the Japanese population","volume":"59","author":"Miki","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.107754_bib64","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/OPTH.S160956","article-title":"Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy","volume":"12","author":"Mohabati","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","article-title":"Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy","volume":"126","author":"Mrejen","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0006-2952(85)90123-6","article-title":"Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro","volume":"34","author":"Netchitailo","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.exer.2019.107754_bib67","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.exer.2019.107754_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2017.06.008","article-title":"Central serous chorioretinopathy and glucocorticoids: an update on evidence for association","volume":"63","author":"Nicholson","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib70","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajo.2014.01.022","article-title":"Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"157","author":"Nicol\u00f3","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib71","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.eye.6702563","article-title":"Assessment of macular function by microperimetry in unilateral resolved central serous chorioretinopathy","volume":"22","author":"Ozdemir","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.exer.2019.107754_bib72","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/eye.2016.79","article-title":"The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study","volume":"30","author":"Ozkaya","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.exer.2019.107754_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123764","article-title":"Novel insights into the crosstalk between mineralocorticoid receptor and G protein-coupled receptors in heart adverse remodeling and disease","volume":"19","author":"Parker","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.exer.2019.107754_bib74","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.exer.2019.107754_bib75","first-page":"1526","article-title":"Anti-vascular endothelial growth factor therapy versus photodynamic therapy","volume":"vol. 38","author":"Peiretti","year":"2018"},{"key":"10.1016\/j.exer.2019.107754_bib76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0303-7207(88)90119-0","article-title":"Inhibition of hormonal-induced cAMP and steroid production by inhibitors of pregnenolone metabolism in adrenal and Leydig cells","volume":"60","author":"Penhoat","year":"1988","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.exer.2019.107754_bib77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","article-title":"Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy","volume":"37","author":"Pichi","year":"2016","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib78","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.107754_bib79","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","article-title":"A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior)","volume":"38","author":"Rahimy","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3928\/23258160-20180628-03","article-title":"Predictors of outcome during eplerenone therapy in chronic central serous chorioretinopathy:A prospective, open-label pilot clinical study","volume":"49","author":"Rajesh","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.exer.2019.107754_bib81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9394(83)90265-9","article-title":"Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy","volume":"95","author":"Robertson","year":"1983","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib82","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1073\/pnas.90.18.8643","article-title":"Microphotocoagulation: selective effects of repetitive short laser pulses","volume":"90","author":"Roider","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.exer.2019.107754_bib83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3928\/23258160-20150422-06","article-title":"Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series","volume":"46","author":"Salz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.exer.2019.107754_bib84","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jfo.2016.01.008","article-title":"[Eplerenone treatment in chronic central serous chorioretinopathy]","volume":"39","author":"Sampo","year":"2016","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.exer.2019.107754_bib85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0014-2999(73)90232-X","article-title":"Cerebral uptake of a 3 H-labelled spirolactone compound in the dog","volume":"21","author":"Schmiedek","year":"1973","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.exer.2019.107754_bib86","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/humu.22551","article-title":"Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy","volume":"35","author":"Schubert","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.exer.2019.107754_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib88","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-016-3378-y","article-title":"Circadian disturbance and idiopathic central serous chorioretinopathy","author":"Setrouk","year":"2016","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib89","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/IAE.0b013e3181e378f2","article-title":"Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy","volume":"31","author":"Shin","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib90","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1097\/IAE.0000000000000621","article-title":"Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy","volume":"35","author":"Shiode","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib91","first-page":"310","article-title":"Oral eplerenone for the management of chronic central serous chorioretinopathy","volume":"8","author":"Singh","year":"2015","journal-title":"Int. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.exer.2019.107754_bib92","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/bjophthalmol-2018-312435","article-title":"Discrepancy in current central serous chorioretinopathy classification","volume":"103","author":"Singh","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib93","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0161-6420(96)30386-2","article-title":"Central serous chorioretinopathy in younger and older adults","volume":"103","author":"Spaide","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib94","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","article-title":"Spironolactone versus observation in the treatment of acute central serous chorioretinopathy","volume":"102","author":"Sun","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib95","article-title":"Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries","volume":"69","author":"Sztechman","year":"2018","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.exer.2019.107754_bib96","article-title":"Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study","volume":"8","author":"Tsai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2019.107754_bib97","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/cvr\/cvy092","article-title":"The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis","volume":"114","author":"van der Heijden","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.exer.2019.107754_bib98","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107754_bib99","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaophthalmol.2017.0245","article-title":"Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy","volume":"135","author":"van Dijk","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.exer.2019.107754_bib100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fendo.2018.00039","article-title":"Cushing's syndrome and hypothalamic-pituitary-adrenal Axis hyperactivity in chronic central serous chorioretinopathy","volume":"9","author":"van Haalen","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.exer.2019.107754_bib101","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib102","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","article-title":"Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology","volume":"104","author":"Wilkinson-Berka","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.exer.2019.107754_bib103","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41433-018-0212-2","article-title":"Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial","volume":"33","author":"Willcox","year":"2019","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.exer.2019.107754_bib104","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/IAE.0000000000001386","article-title":"Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence","volume":"37","author":"Wood","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/08820538.2016.1228418","article-title":"Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy","volume":"32","author":"Yang","year":"2017","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107754_bib106","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-198700720-00009","article-title":"Type-A behavior and central serous chorioretinopathy","volume":"7","author":"Yannuzzi","year":"1987","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib107","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","article-title":"Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study","volume":"23","author":"Yannuzzi","year":"2003","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.107754_bib108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0028-1087188","article-title":"Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis","volume":"41","author":"Ye","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.exer.2019.107754_bib109","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1167\/iovs.11-7675","article-title":"Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina","volume":"52","author":"Zhao","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.107754_bib110","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.exer.2019.107754_bib111","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41467-018-08125-6","article-title":"Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.exer.2019.107754_bib112","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2017.09.029","article-title":"Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site","volume":"266","author":"Zhao","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.exer.2019.107754_bib113","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells","volume":"24","author":"Zhao","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.exer.2019.107754_bib114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40123-018-0121-2","article-title":"Eplerenone versus observation in the treatment of acute central serous chorioretinopathy: a retrospective controlled study","volume":"7","author":"Zucchiatti","year":"2018","journal-title":"Ophthalmol Ther"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519304439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519304439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:56:22Z","timestamp":1777384582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483519304439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":114,"alternative-id":["S0014483519304439"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2019.107754","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2019.107754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107754"}}